Boehringer Ingelheim’s ability to put billions of euros into its pipeline continues to be driven by Jardiance and chairman Hubertus von Baumbach believes that there is plenty more growth to come from the cardiometabolic blockbuster.
Boehringer Still Sees Plenty Of Juice In Jardiance
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
